{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:22:36Z","timestamp":1791318156180,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"a Grant-in-Aid for Young Scientists from the Ministry of Education, Culture, Sports, Science, and Technology of Japan","award":["20K17984"],"award-info":[{"award-number":["20K17984"]}]},{"name":"Japan Osteoporosis Foundation Grant for Bone Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00774-021-01221-6","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T17:02:55Z","timestamp":1617642175000},"page":"824-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis"],"prefix":"10.1007","volume":"39","author":[{"given":"Yumejiro","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-3066","authenticated-orcid":false,"given":"Tomohiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Shimodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotaka","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"1221_CR2","doi-asserted-by":"crossref","unstructured":"Who are candidates for prevention and treatment for osteoporosis? (1997). Osteoporos Int 7:1\u20136","DOI":"10.1007\/BF01623453"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018. https:\/\/doi.org\/10.1016\/S0140-6736(06)68891-0","journal-title":"Lancet"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22:21\u201326. https:\/\/doi.org\/10.1007\/s00198-010-1274-6","journal-title":"Osteoporos Int"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","volume":"19","author":"FJ Penning-van Beest","year":"2008","unstructured":"Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511\u2013517. https:\/\/doi.org\/10.1007\/s00198-007-0466-1","journal-title":"Osteoporos Int"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00198-011-1668-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565\u20132573. https:\/\/doi.org\/10.1007\/s00198-011-1668-0","journal-title":"Osteoporos Int"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00198-013-2365-y","volume":"24","author":"KR Olsen","year":"2013","unstructured":"Olsen KR, Hansen C, Abrahamsen B (2013) Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs\u2013an analysis using national health databases. Osteoporos Int 24:2639\u20132647. https:\/\/doi.org\/10.1007\/s00198-013-2365-y","journal-title":"Osteoporos Int"},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4065\/80.7.856","volume":"80","author":"RR Recker","year":"2005","unstructured":"Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856\u2013861. https:\/\/doi.org\/10.4065\/80.7.856","journal-title":"Mayo Clin Proc"},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cotte","year":"2010","unstructured":"Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155. https:\/\/doi.org\/10.1007\/s00198-009-0930-1","journal-title":"Osteoporos Int"},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199\u20131207. https:\/\/doi.org\/10.1056\/NEJMoa2001316","journal-title":"N Engl J Med"},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11:401\u2013419. https:\/\/doi.org\/10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.08090110.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.08090110.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","volume":"25","author":"JP Brown","year":"2014","unstructured":"Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 25:1953\u20131961. https:\/\/doi.org\/10.1007\/s00198-014-2692-7","journal-title":"Osteoporos Int"},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354. https:\/\/doi.org\/10.1016\/j.bone.2013.10.006","journal-title":"Bone"},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10067-010-1486-3","volume":"29","author":"M Maricic","year":"2010","unstructured":"Maricic M (2010) The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 29:1079\u20131084. https:\/\/doi.org\/10.1007\/s10067-010-1486-3","journal-title":"Clin Rheumatol"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.12968\/hmed.2011.72.10.576","volume":"72","author":"K Walker-Bone","year":"2011","unstructured":"Walker-Bone K (2011) Preventing fractures in the elderly. Br J Hosp Med (Lond) 72:576\u2013581. https:\/\/doi.org\/10.12968\/hmed.2011.72.10.576","journal-title":"Br J Hosp Med (Lond)"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","volume":"28","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T, Taguchi A, Tanaka S, Ohashi M, Ota Y, Shiraki M (2017) Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int 28:389\u2013398. https:\/\/doi.org\/10.1007\/s00198-016-3736-y","journal-title":"Osteoporos Int"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11657-018-0509-6","volume":"13","author":"T Yoshizawa","year":"2018","unstructured":"Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13:94. https:\/\/doi.org\/10.1007\/s11657-018-0509-6","journal-title":"Arch Osteoporos"},{"key":"1221_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00774-018-0928-x","volume":"37","author":"T Asano","year":"2019","unstructured":"Asano T, Shimizu T, Takahashi D, Ota M, Sato D, Hamano H, Hiratsuka S, Takahata M, Iwasaki N (2019) Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. J Bone Miner Metab 37:351\u2013357. https:\/\/doi.org\/10.1007\/s00774-018-0928-x","journal-title":"J Bone Miner Metab"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bone.2017.10.013","volume":"106","author":"M Ito","year":"2018","unstructured":"Ito M, Sone T, Shiraki M, Tanaka S, Irie C, Ota Y, Nakamura T (2018) The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis. Bone 106:179\u2013186. https:\/\/doi.org\/10.1016\/j.bone.2017.10.013","journal-title":"Bone"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43:1243\u20131246. https:\/\/doi.org\/10.1111\/imj.12283","journal-title":"Intern Med J"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"756 e1-2","DOI":"10.1016\/j.ajem.2012.11.011","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31:756 e1\u20132. https:\/\/doi.org\/10.1016\/j.ajem.2012.11.011","journal-title":"Am J Emerg Med"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 8:295\u2013306. https:\/\/doi.org\/10.2147\/TCRM.S24239","journal-title":"Ther Clin Risk Manag"},{"key":"1221_CR25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479. https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J Bone Miner Res"},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K (2017) Factors associated with acute-phase response of bisphosphonate-naive or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int 28:1995\u20132002. https:\/\/doi.org\/10.1007\/s00198-017-3992-5","journal-title":"Osteoporos Int"},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00774-019-01050-8","volume":"38","author":"N Okimoto","year":"2020","unstructured":"Okimoto N, Sakai A, Yoshioka T, Kobayashi T, Asano K, Akahoshi S, Ishikura T, Fukuhara S, Fuse Y, Mizuno T, Katae Y (2020) Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab 38:230\u2013239. https:\/\/doi.org\/10.1007\/s00774-019-01050-8","journal-title":"J Bone Miner Metab"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49:605\u2013612. https:\/\/doi.org\/10.1016\/j.bone.2011.07.011","journal-title":"Bone"},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","volume":"42","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36\u201342. https:\/\/doi.org\/10.1016\/j.bone.2007.09.001","journal-title":"Bone"},{"key":"1221_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-014-2993-x","volume":"26","author":"K Ebina","year":"2015","unstructured":"Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2015) Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda. Osteoporos Int 26:1445. https:\/\/doi.org\/10.1007\/s00198-014-2993-x","journal-title":"Osteoporos Int"},{"key":"1221_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4158\/EP14106.OR","volume":"21","author":"KC Sheedy","year":"2015","unstructured":"Sheedy KC, Camara MI, Camacho PM (2015) Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr Pract 21:275\u2013279. https:\/\/doi.org\/10.4158\/EP14106.OR","journal-title":"Endocr Pract"},{"key":"1221_CR33","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170. https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metab"},{"key":"1221_CR34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jsbmb.2006.12.088","volume":"103","author":"T Matsumoto","year":"2007","unstructured":"Matsumoto T, Kubodera N (2007) ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 103:584\u2013586. https:\/\/doi.org\/10.1016\/j.jsbmb.2006.12.088","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1221_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","volume":"41","author":"M McClung","year":"2007","unstructured":"McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122\u2013128. https:\/\/doi.org\/10.1016\/j.bone.2007.03.011","journal-title":"Bone"},{"key":"1221_CR36","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa K, Nagai T, Sakamoto K, Ohara K, Eguro T, Ito H, Toyoshima Y, Kokaze A, Toyone T, Inagaki K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831\u20131840. https:\/\/doi.org\/10.2147\/TCRM.S123172","journal-title":"Ther Clin Risk Manag"},{"key":"1221_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"1221_CR38","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20134387. https:\/\/doi.org\/10.1210\/jc.2010-0597","journal-title":"J Clin Endocrinol Metab"},{"key":"1221_CR39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1359\/jbmr.090819","volume":"25","author":"F Bertoldo","year":"2010","unstructured":"Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V (2010) Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res 25:447\u2013454. https:\/\/doi.org\/10.1359\/jbmr.090819","journal-title":"J Bone Miner Res"},{"key":"1221_CR40","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E (2011) Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 22:2337\u20132345. https:\/\/doi.org\/10.1007\/s00198-010-1448-2","journal-title":"Osteoporos Int"},{"key":"1221_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00198-011-1563-8","volume":"23","author":"JD Wark","year":"2012","unstructured":"Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J 3rd, Mesenbrink P, de Villiers TJ (2012) Treatment with acetaminophen\/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int 23:503\u2013512. https:\/\/doi.org\/10.1007\/s00198-011-1563-8","journal-title":"Osteoporos Int"},{"key":"1221_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00223-012-9577-6","volume":"90","author":"A Catalano","year":"2012","unstructured":"Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A (2012) Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis. Calcif Tissue Int 90:279\u2013285. https:\/\/doi.org\/10.1007\/s00223-012-9577-6","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-021-01221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:05:30Z","timestamp":1744185930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-021-01221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1007\/s00774-021-01221-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Yumejiro Nakamura, Tomohiro Shimizu, Tsuyoshi Asano, Shun Shimodan, Hotaka Ishizu, Daisuke Takahashi, Masahiko Takahata and Norimasa Iwasaki declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}